ALB · Q3 2025 Earnings

Cautious

Albemarle Corporation

Reported November 5, 2025

30-second summary

30-second take: Albemarle reported Q3 revenue of $1.31B (-3.5% YoY) and adjusted EBITDA of $226M at a 17.3% margin — a meaningful step down from Q2's 25.3% as energy storage pricing eroded another -16% YoY against +8% volume. The signal: management quantified FY free cash flow at $300-400M (up from "positive"), cut FY capex again to ~$600M (from $650-700M), and pushed the cost program to $450M run-rate. But Q4 FCF is now guided "modestly negative," Specialties Q4 EBITDA is going lower on oil & gas weakness, and management explicitly will not restart mothballed capacity in 2026 — confirming this is a multi-year defensive posture, not a cyclical bottom.

Headline numbers

EPS

Q3 FY2025

$-0.19

Revenue

Q3 FY2025

$1.31B

-3.5% YoY

Gross margin

Q3 FY2025

9.0%

Operating margin

Q3 FY2025

-16.6%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$1.31B	-3.5%	$1.33B	-1.7%
EPS	$-0.19	—	$0.11	-272.7%
Gross margin	9.0%	—	14.8%	-581bps
Operating margin	-16.6%	—	3.6%	-2020bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2025	$4.9 - $5.2 billion (full year)	$1.308 billion	In-line with quarterly run-rate within full-year guide	Met

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Free Cash Flow	FY2025	Positive	$300 to $400 million	Upgraded from qualitative 'positive' to quantified $300–$400M range	Raised
Capital Expenditures	FY2025	$650 - $700 million	approximately $600 million	-$50M to -$100M reduction at midpoint	Lowered
Cost and productivity improvements	FY2025	$400 million (100% run-rate against target)	approximately $450 million (surpassing initial $300–400M target)	+$50M above prior target	Raised

Reaffirmed unchanged this quarter: Adjusted EBITDA ($0.8 - $1.0 billion), Energy Storage net sales ($2.5 - $2.6 billion), Energy Storage Adjusted EBITDA ($0.6 - $0.7 billion), Specialties net sales ($1.3 - $1.5 billion), Specialties Adjusted EBITDA ($210 - $280 million), Ketjen net sales ($1.0 - $1.1 billion), Ketjen Adjusted EBITDA ($120 - $150 million)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Energy Storage	$0.709B	-7.6%
Specialties	$0.345B	+0.8%
Ketjen	$0.254B	+3.7%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Energy Storage Volume Growth	+8%
Energy Storage Pricing Impact	-16%
Ketjen Volume Growth	+8%
Adjusted EBITDA	$225.6 million
Adjusted EBITDA Margin	17.3%
Operating Cash Flow (9M)	$893.8 million
Full-Year FCF Guidance	$300-$400 million
Net Debt to Adjusted EBITDA	2.1x

Management tone

Customer optimization hangover → Cost program acceleration → FCF flip to positive → FCF quantified, but Q4 turns negative

The FCF narrative tightened from directional to numeric, but Q4 flips negative. Two quarters ago FCF was "break-even"; last quarter it became "positive"; this quarter it is "$300-400M for the full year." That's a meaningful sharpening of commitment, supported by $893.8M of 9-month operating cash flow. But the same quarter introduces this: "Based on our free cash flow outlook, we expect modestly negative free cash flow in Q4." The arc reveals the FCF beat is essentially already in the bag from the first nine months, and forward cash generation is softening as price compression catches up with the cost program.

The cost-program framing shifted from "achieved" to "exceeded." Last quarter management celebrated hitting 100% run-rate against the original $300-400M target six months early. This quarter: "We began the year with a goal of $300 to $400 million in improvements. Today, we've achieved a $450 million run rate, exceeding the high end of our initial target." The signal isn't the $50M increment — it's that cost extraction has become the central operating story, replacing volume growth or price recovery as the primary value driver. That works until it doesn't.

Capacity restart was explicitly ruled out for 2026. A quarter ago management hinted at supply-side rebalancing in 2026-2027 without committing. In Q&A this quarter Jeffrey Zakakis directly asked about restarting mothballed plants; Kent Masters responded that "timeline to bring capacity back online is longer than the timeframe being evaluated" and ruled out restarts in 2025 or 2026. This is more discipline than prior commentary suggested but also a tacit acknowledgment that prices will not recover fast enough in 2026 to justify it.

The contract-floor cushion shrank from ~50% to ~45%. Last quarter management cited ~50% of the portfolio on long-term agreements with floors as the downside protection. This quarter: "We now expect approximately 45% of our 2025 lithium salts volumes to be sold on long-term agreements with floors, primarily due to the mixed impact of stronger-than-expected volumes in China." A higher proportion of volume is now spot-exposed than was guided three months ago — a quiet but material reduction in downside protection.

Recurring themes management leaned on this quarter:

Cost discipline and productivity offsetting commodity pricing headwindsStrong cash generation and capital allocation disciplineEnergy storage volume growth acceleration driven by China and North AmericaMargin resilience despite lower lithium pricesLong-term structural demand from EVs and stationary storageAsset sales providing financial flexibility

Risks management surfaced:

Lower lithium market prices pressuring net salesExposure to commodity price volatility with only 45% of volumes on long-term agreements with floorsWeaker demand in oil and gas applications affecting specialties segment Q4Q4 free cash flow expected to be modestly negative due to timing of interest payments and working capital needsLapidolite curtailments in China impacting global lithium supply

Q&A highlights

Aleksi Yefermov · KeyBank

How will Atlas lithium margins evolve in H1 2026 given spodumene price dynamics? Will higher spodumene costs be offset by equity income?

Management indicated margin movements depend on relative price movements between salt and spodumene. They operate an integrated network and are indifferent between the two from a margin perspective. Taliesin inventory accounting creates a 6-9 month lag in recognizing equity earnings benefits as spodumene is consumed.

6-9 month inventory lag for spodumene cost realizationRecent trend: margin moves to spodumene resource when prices move upIntegrated network provides flexibility between salt and spodumene margin capture

Jeffrey Zakakis · JP Morgan

What is the current China spodumene price and will Albemarle restart any mothballed production capacity?

Current China spodumene price closer to $10/kg vs. $11/kg, with full-year 2025 average around $9-9.50/kg. Management stated they will not restart mothballed plants in remaining 2025 or 2026; timeline to bring capacity back online is longer than the timeframe being evaluated.

Current China spodumene price: ~$10/kgFull-year 2025 average price guidance: $9.00-9.50/kgNo plans to restart mothballed production in 2025-2026

John Roberts · Mizuho

What is the EV vs. energy storage demand split and how does management see those percentages evolving medium-term?

Fixed energy storage currently ~25% of lithium market but growing 2x+ faster than EVs. Long-term market expected to remain more EV-oriented. Fixed storage more exposed to substitute technologies (sodium-ion) than EVs. Range suggests fixed storage could reach ~50% of market long-term but depends on technology substitution dynamics.

Fixed storage today: ~25% of lithium demandEnergy storage growth rate: 2x+ faster than EV demandLong-term fixed storage could reach ~50% of market (uncertain)80% of long-term storage expected to remain lithium-ion technology

David Begletter · Deutsche Bank

How much Chinese lapidolite supply has been curtailed and what is the impact? Has Albemarle's 2030 lithium demand outlook changed?

About one-third of Chinese lapidolite production (8 operations including CATL) impacted by permitting exercises, representing ~30,000 tons annual reduction. However, impact assessed as minor (couple percent of supply annually). 2030 lithium demand outlook unchanged in range but shifted higher within that range, particularly for EV and fixed storage. Demand proving stronger than early-year expectations.

Chinese lapidolite production curtailed: ~33% or ~30,000 tons annually8 operations affected including largest producer CATLImpact on total supply: ~2% annually if all remain down2030 demand forecast: unchanged range but shifted up internally; stronger EV and storage demand vs. expectations

Lawrence Alexander · Jefferies

What are Albemarle's return hurdles for new projects vs. optimizing existing assets? Will Kings Mountain economics improve? Can the company be free cash flow positive at lower prices in 2026?

Return criteria unchanged; pricing environment prevents meeting hurdles, which is why no new investments announced. Focus on cost reduction and balance sheet strength to compete through cycle bottom. Kings Mountain and conversion economics still not viable at western economics levels. Management not forecasting 2026 cash flow but confident cost structure improvements will allow navigation of volatility without predicting results.

Return hurdles: unchanged and unmet by current pricingKings Mountain and Western conversion economics: not viable todayProductivity savings run-rate: $450 million achieved in 2025Strategy: ride through downside, capture upside; maintain cost discipline

Answers to last quarter's watch list

November 2025 debt maturity resolution. The company didn't disclose specific refinancing terms in this print, but with 9-month operating cash flow of $893.8M and net debt/EBITDA improving to 2.1x (from 2.3x in Q2), the balance sheet has materially strengthened heading into the maturity.

Continue monitoring

Q3 Energy Storage EBITDA margin holding in the mid-20s. Total-company adjusted EBITDA margin compressed to 17.3% from Q2's 25.3%. Energy Storage segment EBITDA implies ~21% margin against the watch threshold of ~22% — landing right at the line. Cost program savings are flowing but not fast enough to fully offset -16% pricing.

Resolved negatively

2026 capex framework. FY2025 capex cut again to ~$600M (from $650-700M). Management did not give a specific 2026 number but ruled out restarting mothballed capacity in 2026, which suggests capex stays disciplined. The directional signal is clear; the absolute number is not.

Continue monitoring

Lithium realized pricing vs. the $9/kg basket assumption. The basket assumption was nudged up to ~$9.50/kg, but the contract-floor cushion shrank from ~50% to ~45%, partially offsetting the price tailwind. Pricing held, but the protection thinned.

Resolved positively

Supply-side capacity exits. Management quantified ~30,000 tons of Chinese lapidolite curtailment (~33% of that source, ~2% of global supply) but characterized the impact as minor. No concrete signal of broader Western capacity exits. The 2027+ deficit thesis remains unsupported by hard capacity announcements.

Not resolved

What to watch into next quarter

Q4 free cash flow trajectory vs. the "modestly negative" guide. Management explicitly flagged Q4 FCF turning negative. A print materially worse than "modestly negative" (say, below -$100M) would imply the $300-400M full-year FCF is at the bottom of the range or below.

Energy Storage Q4 EBITDA margin sequential progression. Management guided "slightly higher sequentially" on EBITDA. Watch whether segment EBITDA margin recovers above ~22% in Q4 or stays compressed near 20% — a sustained sub-22% print would indicate cost savings have plateaued against ongoing price pressure.

Specialties Q4 EBITDA decline magnitude on oil & gas weakness. Management said Q4 EBITDA will be "lower" but didn't quantify. With the FY $210-280M range reaffirmed at a wide $70M spread, a Q4 print near $40-50M would test the low end and signal 2026 starting point.

2026 capex disclosure. Management deferred specifics but has now reduced 2025 capex twice. Watch the Q4 print for an explicit 2026 capex framework — flat-to-down vs. ~$600M is the bull case; a step-up signals JV commitments forcing the hand.

Talison spodumene cost flow-through timing. Per Q&A, the 6-9 month inventory lag means recent spodumene price moves up will benefit equity income in H1 2026. Watch Q4 commentary for explicit equity income guidance — this is the cleanest 2026 margin tailwind management has flagged.

Long-term contract floor percentage. The cushion shrank from ~50% to ~45% this quarter. Another step-down toward 40% in 2026 disclosures would materially increase spot exposure and downside risk.

Sources

Albemarle Q3 2025 Earnings Release, SEC Filing (Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/915913/000091591325000160/a3q25earningsreleaseex991.htm
Albemarle Q3 2025 earnings call commentary (management prepared remarks and Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.